Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hepatic encephalopathy
Comorbidity C0023895|liver disease
Sentences 15
PubMedID- 25867912 Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
PubMedID- 24498036 Considered non-aids events included non-aids malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease.
PubMedID- 22228885 The aim of this study was to evaluate scientific evidence for the effectiveness and safety of lola infusions for treatment of clinical hepatic encephalopathy in patients with chronic liver disease.
PubMedID- 25908985 These include hepatic encephalopathy in patients with advanced liver disease, vascular bypass of the liver, valproic acid or cyclophosphamide poisoning, herpes simplex infection, and gastrointestinal bacterial overgrowth.
PubMedID- 20728575 No state specifically mentioned hepatic encephalopathy or patients with advanced liver disease.
PubMedID- 26029995 Objectives: acute liver failure is a life-threatening condition with sudden onset liver injury, decreased liver functions, hepatic encephalopathy, and coagulopathy in patients without preexisting liver disease.
PubMedID- 22867045 All opioid drugs can precipitate or aggravate hepatic encephalopathy in patients with severe liver disease, thus requiring cautious use and careful monitoring.
PubMedID- 20335583 Methods: in this randomized, double-blind, placebo-controlled trial, we randomly assigned 299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients), or placebo (159 patients) for 6 months.
PubMedID- 23978689 Alf is characterized by coagulopathy and hepatic encephalopathy (he) in a patient without pre-existing liver disease.
PubMedID- 21384402 Additional studies are warranted to evaluate the effects of ast-120 on hepatic encephalopathy in patients with advanced liver disease.
PubMedID- 21741091 Rifaximin received new labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (he) in patients with advanced liver disease in march of 2010.
PubMedID- 24133449 Alf results from the acute and rapid loss of hepatocyte function, and is associated with coagulopathy [international normalized ratio (inr) >1.5] and hepatic encephalopathy (he) in a patient without pre-existing liver disease.
PubMedID- 25586470 Objectives: rifaximin is approved for the reduction of hepatic encephalopathy (he) recurrence in patients with chronic liver disease (cld); however, few studies have evaluated the benefit of adding rifaximin to lactulose for treatment of acute he.
PubMedID- 25374719 Acute liver failure is characterized by the rapid development of severe liver injury with impaired synthetic function and hepatic encephalopathy in a patient without obvious, previous liver disease.
PubMedID- 25733099 The primary outcome was drug-induced alf (defined as coagulopathy and hepatic encephalopathy without underlying chronic liver disease), determined by hepatologists who reviewed medical records of all kpnc members with inpatient diagnostic and laboratory criteria suggesting potential alf.

Page: 1